NCT06488313Phase 2Recruiting

A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

Study sponsor: Arcturus Therapeutics, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-06-01Estimated
Enrollment · participants9Estimated
Source updated2025-03-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.